Favorable Prospects For UCB In 1996
Prospects for the development of the UCB group in 1996 remain favorable, according to a statement released by the Belgian firm at its annual general meeting. However, UCB added that it must be remembered that its R&D and investment efforts remain significant.
The company is investing around 9 billion Belgian francs ($288.1 million) this year, comprising of an R&D budget of 4.6 billion francs, and an investment program of 4.3 billion francs.
UCB said that its pharmaceutical sector continues to progress, mainly driven by sales of its antiallergy agent Zyrtec (cetirizine), which has benefited further from its launch in the USA (Marketletters passim). Sales to date show that the product has been received most favorably there by the medical profession, said the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze